Sign in

UCSF Center for Tuberculosis

@ucsf-ctb.bsky.social
37 followers 8 following 7 posts

Accelerating TB Research - Training the Next Generation of TB Scientists - Innovative Discoveries - Translation of Evidence to Policy, Practice, Diplomacy.

PostsRepliesMedia
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 12/03/2026
What drives hepatotoxicity in standard TB therapy? In Clinical Infectious Diseases, we show that higher pyrazinamide and isoniazid exposures—and slow NAT2 acetylator status—are linked to increased hepatotoxicity, while rifampin exposure (up to 20 mg/kg) is not. academic.oup.com/cid/advance-...
academic.oup.com
Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis
Higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were independently associated with hepatotoxicity. In multivariable analysis, o
010
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 10/03/2026
Tongue swabs match sputum for TB diagnostic yield — and 100% of patients could provide one vs. 85% for sputum. 1,639 participants across Philippines, Vietnam, Uganda & Zambia. Non-inferior results. Big implications for kids & PLHIV. academic.oup.com/cid/advance-...
academic.oup.com
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
Tongue swab molecular testing with the MiniDock MTB Test achieved non-inferior diagnostic yield compared to sputum-based molecular testing, supporting adop
021
Reposted by UCSF Center for Tuberculosis
Devan Jaganath, MD MPH @djaganath.bsky.social · 11/02/2026
With the ongoing #TB outbreak at an SF high school, we will leverage our expertise in child TB, with the @citc-tb.bsky.social and @ucsf-ctb.bsky.social. @ucsfchildrens.bsky.social is working closely with SF public health to support students and families. pediatrics.ucsf.edu/news/access-...
pediatrics.ucsf.edu
Access in Action: How UCSF is Expanding Care to Support San Francisco’s Pediatric TB Response | Department of Pediatrics
When a tuberculosis (TB) outbreak emerged at a San Francisco high school at the end of 2025, the scale was immediately clear. More than 1,200 students required evaluation, with high rates of infection...
044
Reposted by UCSF Center for Tuberculosis
Devan Jaganath, MD MPH @djaganath.bsky.social · 16/01/2026
#tbsky #idsky We modeled the use of child TB treatment decision algorithms - providing primary care facilities with diagnostics is lower cost than referring all to district facilities, but we need to still improve specificity and reduce treatment costs: journals.theunion.org/content/ijtl...
journals.theunion.org
Integrated treatment-decision algorithms for childhood TB: modelling diagnostic performance and costs
SUMMARYBACKGROUNDTo improve childhood TB diagnosis, treatment-decision algorithms (TDAs) with and without chest X-ray (CXR) were developed for children under age 10. We aimed to model diagnostic performance and costs of implementing TDAs in primary health centre (PHC) and district hospital (DH) settings in Uganda.METHODSWe developed decision-tree models following the TDA pathway from evaluation to treatment-decision. We compared six scenarios with combinations of diagnostic testing (stool and respiratory Xpert, urine lipoarabinomannan, and/or CXR) at PHCs and DHs. Outcomes were diagnostic accuracy and cost per correct treatment-decision for a cohort of 10,000 children with presumptive TB using a Monte Carlo simulation from a health system perspective. Costs were reported in 2024 international dollars (I$).RESULTSIn all scenarios, TDAs had high sensitivity (80.8%–91.9%) but low specificity (50.9%–60.9%). Total diagnostic and treatment costs for the cohort were I$1,768,958–2,470,298, largely driven by overtreatment of false-positive cases. Diagnostic costs were mostly offset by reducing overtreatment. The cost per treatment-decision was lowest using mobile CXR at PHCs (I$287) and highest with DH referral (I$449).CONCLUSIONThe TDAs have high sensitivity and can be implemented at PHCs with lower costs than DHs. Improving specificity and reducing treatment costs would enable affordable, large-scale implementation.
042
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 05/01/2026
This SF clinical experience explores the use of linezolid for rifampin-susceptible #tuberculosis (RS-TB) — a drug typically reserved for resistant disease — in a diverse urban patient population. lnkd.in/eQaRpf5f
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
011
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 19/09/2025
🚨 Satellite session at #UnionConf2025! “Transforming TB detection with tongue swab-based molecular testing” 🗓️ Nov 19 | 8–9AM | Copenhagen Beyond sputum: tongue swabs + near-POC molecular tools. unionconf2025.abstractserver.com/programme/#/... #TB #GlobalHealth #Diagnostics
011
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 16/09/2025
Can a smartphone-recorded cough help detect #TB? The CODA TB DREAM Challenge shows promise: AI + clinical data reached 73.8% specificity at 80% sensitivity across 7 countries. Read more: academic.oup.com/ofid/advance...
academic.oup.com
Accelerating cough-based algorithms for pulmonary tuberculosis screening: Results from the CODA TB DREAM Challenge
AbstractBackground. Open-access data challenges can accelerate innovation in artificial-intelligence (AI)-based tools. In the Cough Diagnostic Algorithm fo
011
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 08/09/2025
New Lancet study in Philippines, Vietnam, South Africa, Uganda & India: People tested for #TB prioritize diagnostics that are • Low-cost • Accurate • Deliver results in 15 minutes Findings show need to align WHO TPPs with patient preferences. www.thelancet.com/journals/lan...
thelancet.com
Preferences for tuberculosis diagnostic test features among people tested for tuberculosis: a multicountry discrete choice experiment
Individuals accessing tuberculosis services across high-burden settings universally value low to no cost tests, high diagnostic accuracy, and rapid result availability. These findings underscore the n...
011
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 25/08/2025
Join us for Innovating Against #TB – Community Solutions to TB Challenges 📅 Thurs, Sept 11, 2025 🕐 1–2 PM PT | 4 PM ET ✅ Up to 1 CE hour Hear from leaders & advocates on TB programs driving change via education, advocacy & services. 🔗 Register: us02web.zoom.us/meeting/regi... #Tuberculosis
us02web.zoom.us
Welcome! You are invited to join a meeting: Innovating Against TB - Community Driven Solutions to TB Challenges. After registering, you will receive a confirmation email about joining the meeting.
Please join the Coalition for a TB Free California (CTFC) and the Association of Asian and Pacific Health Organizations (AAPCHO) for an engaging webinar highlighting three innovative TB programs that ...
011
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 29/07/2025
Results from the endTB-Q trial (MSF, PIH, IRD, UCSF CTB): BDLC (bedaquiline, delamanid, linezolid, clofazimine) was not non-inferior to standard regimens for pre-XDR #TB. Longer/stronger treatments may be needed. www.sciencedirect.com/science/arti...
sciencedirect.com
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, c...
Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistance to any fluoroquinolo…
010
Reposted by UCSF Center for Tuberculosis
Devan Jaganath, MD MPH @djaganath.bsky.social · 21/07/2025
We need new biomarkers to improve TB diagnosis in children. In the COMBO study, we performed a comprehensive plasma proteomic analysis across 4 countries and found several protein signatures that met the WHO target accuracy for a TB screening test: www.nature.com/articles/s41... #tbsky #idsky
nature.com
Plasma proteomics for biomarker discovery in childhood tuberculosis - Nature Communications
In this work, through a comprehensive proteomics approach, the authors identified host plasma protein biosignatures that could distinguish tuberculosis (TB) disease in children.
187
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 30/06/2025
Can digital adherence tools improve #TB care at scale? We evaluated 99DOTS in Uganda during national scale-up. High uptake (87%), no harm to outcomes, but equity in access remains key. Read more: www.medrxiv.org/content/10.1... #tuberculosis
medrxiv.org
Scale-up of 99DOTS for tuberculosis treatment supervision in Uganda: An interrupted time series analysis
Background Digital adherence technologies like 99DOTS are being scaled-up for tuberculosis (TB) treatment despite limited evidence of their effectiveness and concerns about accessibility. We evaluated...
041
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 17/04/2025
In our study of 2,904 adults with #TB symptoms across five high TB-burden countries, CRP-based screening had 84% sensitivity and 61% specificity. Though CRP didn’t meet minimum diagnostic targets overall, its accuracy varied by setting and subgroup. www.atsjournals.org/doi/10.1164/...
atsjournals.org
C-Reactive Protein–based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study | American Journal of Respiratory and Critical Care Medicine
021
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 15/04/2025
WHO announces landmark changes in treatment of drug-resistant #tuberculosis createsend.com/t/d-0CC16B59...
createsend.com
WHO announces landmark changes in treatment of drug-resistant tuberculosis
120
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 15/04/2025
Dr. Ann M Loeffler will be presenting on advances and local strategies in pediatric #TB at the UCSF Department of Pediatrics Grand Rounds this Thursday, April 17th, from 12-1pm. Attend in person at Oberndorf Auditorium or via Zoom: bit.ly/3Go7Np2
010
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 09/04/2025
Our study compared Uganda’s #TB treatment decision algorithm for children with the WHO's. We found these TDAs can help diagnose more TB cases, but could also lead to overtreatment. Better tests are needed to confirm TB in children. dx.plos.org/10.1371/jour... #Tuberculosis #ChildHealth #Uganda #WHO
dx.plos.org
The Accuracy of the Uganda National Tuberculosis and Leprosy Program diagnostic algorithm and the World Health Organisation treatment decision algorithms for childhood tuberculosis: A retrospective an...
Author summary In this study, we assessed and compared the accuracy of the 2017 Uganda National TB and Leprosy Program (NTLP) algorithm with the 2022 World Health Organization (WHO) Treatment Decision...
021
Reposted by UCSF Center for Tuberculosis
UC TB Innovation for Impact Collaboratory @tb-innovation.bsky.social · 26/03/2025
Despite being preventable, #TB affects thousands in the US. A major barrier to TB elimination is the lack of Medicare coverage for TB infection screening and testing. Our team describes how this policy gap affects US TB elimination efforts. rdcu.be/efcBa #TBPrevention #Medicare #CTB
rdcu.be
Policy Impediments to Tuberculosis Elimination: Consequences of an Absent Medicare National Coverage Determination for Tuberculosis Prevention
013
UCSF Center for Tuberculosis @ucsf-ctb.bsky.social · 08/03/2025
Learn about how faculty at the UCSF Center for Tuberculosis are waging the fight against #TB www.ucsf.edu/news/2025/03...
ucsf.edu
The Fight Against TB Was Frozen in Time, Until Now. See Its Future
Tuberculosis has stalked humanity for as nearly as long as we've been on earth. In this article, we take a look at how UCSF is leading the fight against the leading infectious disease killer.
010